High-affinity monoclonal antibodies for botulinum toxin type A
View Patent ↗High affinity antibodies for binding epitopes of BoNT/Aand hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/A in a sample.
1. An isolated and purified monoclonal antibody produced by the continuous hybridoma cell line having deposit accession number ATCC PTA-8336.
2. A composition comprising the monoclonal antibody of claim 1 .
3. An isolated and purified monoclonal antibody produced by the continuous hybridoma cell line having deposit accession number ATCC PTA-8337.
4. A composition comprising the monoclonal antibody of claim 3 .
5. An isolated and purified monoclonal antibody produced by the continuous hybridoma cell line having deposit accession number ATCC PTA-8338.
6. A composition comprising the monoclonal antibody of claim 5 .
7. A kit for detecting BoNT/A in a sample, said kit comprising: (1) a container comprising a monoclonal antibody selected from the group consisting of ATCC PTA-8336, ATCC PTA-8337, ATCC PTA-8338, ATCC PTA-8339, and mixtures thereof; and (2) instructions for using the antibody for the purpose of binding to BoNT/A to form an immunological complex and detecting the formation of the immunological complex such that presence or absence of immunological complex correlates with presence or absence of BoNT/A in said sample.
8. A method for detecting BoNT/A comprising (1) incubating a sample with the monoclonal antibody selected from the group consisting of ATTC PTA-8336, ATCC PTA-8337, ATCC PTA-8338, ATCC PTA-8339, and mixtures thereof; and (2) detecting the antibody-BoNT/A complex wherein the presence or absence of the complex indicates the presence or absence of BoNT/A in the sample.
9. A method for detecting BoNT/A according to claim 8 wherein said sample is aqueous, biological, environmental or a food product.
10. A method for capturing BoNT/A from a sample, said method comprising contacting said sample with the monoclonal of claims 1 , 3 or 5 , and isolating the complex formed between the BoNT/A in the sample and the monoclonal antibody.